

To whom it may concern:

5-2-1 Daizawa, Setagaya Ward, Tokyo
 TOHO HOLDINGS CO., LTD.
 (Tokyo Stock Exchange Securities Code: 8129)
 Norio Hamada, President and CEO
 Contact:
 Katsuya Kato
 Corporate Officer and General Manager of
 Corporate Communications Office
 (TEL: 03-5259-9520)

Notice of Conclusion of Agreement for Capital and Business Alliance with FUJIFILM Corp.

TOHO HOLDINGS CO., LTD. is pleased to announce that it has concluded an agreement for a capital and business alliance with FUJIFILM Corporation (hereinafter “FUJIFILM”) in connection with FUJIFILM’s newly established subsidiary as follows:

1. Reasons for Business Alliance

TOHO HOLDINGS has concluded an agreement for a capital and business alliance aiming to support manufacturing and sales of pharmaceuticals (generic pharmaceuticals at its inception) developed by FUJIFILM PHARMA CO., LTD. (hereinafter “FUJIFILM PHARMA”) which was newly established for the purpose of a full-scale entry into development and sales of pharmaceuticals by FUJIFILM. TOHO HOLDINGS intends to establish a reliable and reassuring pharmaceutical distribution focusing on the realization of traceability of pharmaceuticals to patients and value of products through a stable supply of pharmaceuticals that will be selected, evaluated and procured based on the quality assurance standard established independently by FUJIFILM PHARMA.

2. Outline of Capital and Business Alliance

- (1) TOHO HOLDINGS’ capital participation in FUJIFILM PHARMA (5%)
- (2) TOHO PHARMACEUTICAL, a subsidiary of TOHO HOLDINGS, is in charge of sales and distribution of FUJIFILM PHARMA’s products and will promote sales activities and a stable supply to domestic medical institutions.

3. Characteristics

- (1) FUJIFILM PHARMA will strive to promote highly reliable generic pharmaceuticals by establishing “FUJIFILM PHARMA’s unique quality assurance standard for pharmaceuticals” consisting mainly of “Three pillars of quality control.”*
 * 「Quality control of raw materials」 「Control of manufacturing processes and design quality」 「Post-sale quality control」
- (2) TOHO HOLDINGS will construct a stable supply system for FUJIFILM PHARMA’s products by using the “accurate,” “speedy” and “stable” distribution network of TOHO PHARMACEUTICAL.

4. Outline of FUJIFILM Pharma Corporation

Company name	FUJIFILM Pharma Corporation
Main business contents	R&D, manufacturing, marketing, exportation and importation of pharmaceutical products
Establishment	November 2, 2009
Capital	50 million yen
Shareholders	FUJIFILM :80%, Mitsubishi Corporation:15%, TOHO HOLDINGS:5%
Representative Director	Kanji Yagi
Commencement of business operations	April 2010 (Planned)